Organovo (NASDAQ:ONVO) Now Covered by StockNews.com

Stock analysts at StockNews.com began coverage on shares of Organovo (NASDAQ:ONVO) in a research report issued on Sunday. The brokerage set a “sell” rating on the medical research company’s stock.

Organovo Trading Down 2.6 %

Shares of Organovo stock opened at $0.37 on Friday. The business has a fifty day simple moving average of $0.38 and a two-hundred day simple moving average of $0.44. The firm has a market capitalization of $6.44 million, a P/E ratio of -0.43 and a beta of 0.54. Organovo has a 12 month low of $0.32 and a 12 month high of $1.74.

Organovo (NASDAQ:ONVO) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.02. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.05 million. Organovo had a negative return on equity of 346.26% and a negative net margin of 10,151.64%. Analysts predict that Organovo will post -0.77 earnings per share for the current year.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.